NASATAPP Reviewed by Momizat on . Brand Name: NASATAPP is the combination of the decongestant, Phenylpropanolamine Hydrochloride and antihistamine, Brompheniramine Maleate. This combination redu Brand Name: NASATAPP is the combination of the decongestant, Phenylpropanolamine Hydrochloride and antihistamine, Brompheniramine Maleate. This combination redu Rating:
You Are Here: Home » Drug Study » NASATAPP

NASATAPP

Brand Name:

NASATAPP

is the combination of the decongestant, Phenylpropanolamine Hydrochloride and antihistamine, Brompheniramine Maleate. This combination reduces excessive nasopharyngeal secretion and diminishes inflammatory mucosal edema and congestion in the upper respiratory tract. The antihistamine action of Brompheniramine Maleate reduces or diminishes the allergic response of nasal tissues. It is complemented by the mild vasoconstrictor action of Phenylpropanolamine Hydrochloride, which provides a nasal decongestant effect.
Indications
NASATAPP is indicated for allergic and vasomotor or other hyperactive nasal disorders, acute coryza, for the relief of nasal congestion and hypersecretion in infants, children and adults.

Pharmacokinetics
Phenylpropanolamine is readily and completely absorbed from the gastrointestinal tract with peak plasma concentrations being achieved about an hour or two after oral administration. At theearliest, its decongestant effect is after 15 to 30 minutes. The half-life of Phenylpropanolamine ranges from three to four hours. Phenylpropanolamine and Brompheniramine Maleate are both metabolized in the liver. Phenylpropanolamine is excreted largely unchanged in the urine and Brompheniramine is also excreted in the urine.

Precautions
Sympathomimetic agents such as Phenylpropanolamine Hydrochloride should be used with caution in patients, which may be particularly susceptible to their effects, particularly those with hyperthyroidism. Great care is also needed in patients with cardiovascular disease such as ischemic heart disease, arrhythmia or tachycardia, occlusive vascular disorders including arteriosclerosis, hypertension or aneurysms. Anginal pain may be precipitated in patients with angina pectoris. Care is also required when sympathomimetic agents are given to patients with diabetes mellitus or closed-angle glaucoma, pregnancy, lactation, newborn or premature infants.

Antihistamine should not be given to premature infants or neonates; this group of patients has an increased susceptibility to antimuscarinic effects. Elderly patients are also more susceptible to many adverse effects of antihistamines, including antimuscarinic effects, sedation, and hypotension. Many antihistamines may cause drowsiness; patients so affected should not drive or operate machinery and should avoid alcoholic drink. Because of their antimuscarinic properties, antihistamine should be used with care in conditions such as closed-angle glaucoma, urinary retention, prostatic hypertrophy, or pylorodoudenal obstruction.

Contraindications
Brompheniramine Maleate is contraindicated in patients with known brain damage or epilepsy.

Drug Interaction
Many sympathomimetics interact with monoamine oxidase inhibitors (MAOIs) and should not be given to patients receiving such treatment.

NASATAPP DROPS

Formulation:
Per 1 mL Drop contains:
Phenylpropanolamine Hydrochloride………………6.25 mg
Brompheniramine Maleate………………………….……2.0mg

Dosage and Administration:
To be taken every 6 to 8 hours or as prescribed by the physician
Infants to 6 month……..0.5 mL
months to 2 years………1.0 mL

Availability:
Drops is available in 15 mL bottle

NASATAPP SYRUP 60mL
Formulation:
Per 5 mL (1 teaspoonful) Syrup contains:
Phenylpropanolamine Hydrochloride……………..12.5mg
Brompheniramine Maleate………………………….4.0mg

Dosage and Administration:
To be taken every 6 to 8 hours or as prescribed by the physician
1 month to 6 months…….¼ tsp. (1.25mL)
7 months to 2 years……….½ tsp. (2.5 mL)
2 to 4 years…………………….¾ tsp. (3.75mL)
4 to 12 years……………………1 tsp. (5 mL)

Availability:
Syrup is available in 60 mL bottle 

NASATAPP TABLET

Formulation:
Each Tablet contains:
Phenylpropanolamine Hydrochloride 15mg
Brompheniramine Maleate 12mg

Dosage and Administration:
1 tablet twice a day or as prescribed by physicians.

Warning:

This product contains Tartrazine (FD & C Yellow #5 which may cause allergic reaction including bronchial asthma in certain susceptible person.

Care is necessary if Phenylpropanolamine (PPA) is to be given to patients with high blood pressure, toxic goiter, benign prostatic hypertrophy, heart rate irregularity, glaucoma and to those receiving antidepressant therapies. Patients with heart disease and uncontrolled or untreated high blood pressure should consult a doctor prior to taking PPA.

Availability:
Tablet in blister pack 5 x 20’s (1 box of 100’s)


Scroll to top